Recent studies uncover that PSEN1 and its mutation are considered to negatively regulate the WβC signaling by promoting GSK-3β phosphorylation [65], and PSEN1 mutations are reported in AD patients, with enhanced degradation of β-catenin [66]. This evidence concerns the gene PSEN1 and Alzheimer disease.